NASDAQ:LNAI Lunai Bioworks (LNAI) Stock Price, News & Analysis $2.43 -0.05 (-2.06%) As of 10:43 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Lunai Bioworks Stock (NASDAQ:LNAI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Lunai Bioworks alerts:Sign Up Key Stats Today's Range$2.38▼$2.4850-Day Range$1.94▼$4.3052-Week Range$1.21▼$21.20Volume12,714 shsAverage Volume1.54 million shsMarket Capitalization$11.00 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California. Read More Lunai Bioworks Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks11th Percentile Overall ScoreLNAI MarketRank™: Lunai Bioworks scored higher than 11% of companies evaluated by MarketBeat, and ranked 859th out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingLunai Bioworks has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageLunai Bioworks has only been the subject of 1 research reports in the past 90 days.Read more about Lunai Bioworks' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Lunai Bioworks is -6.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lunai Bioworks is -6.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.70% of the float of Lunai Bioworks has been sold short.Short Interest Ratio / Days to CoverLunai Bioworks has a short interest ratio ("days to cover") of 2.55, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lunai Bioworks has recently decreased by 18.94%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLunai Bioworks does not currently pay a dividend.Dividend GrowthLunai Bioworks does not have a long track record of dividend growth. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 3 news articles for Lunai Bioworks this week, compared to 1 article on an average week.Search Interest1 people have searched for LNAI on MarketBeat in the last 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lunai Bioworks insiders have not sold or bought any company stock.Percentage Held by Insiders0.50% of the stock of Lunai Bioworks is held by insiders.Percentage Held by Institutions71.41% of the stock of Lunai Bioworks is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lunai Bioworks' insider trading history. Receive LNAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lunai Bioworks and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LNAI Stock News HeadlinesLunai Bioworks (NASDAQ:LNAI) Stock Price Down 2.7% - Here's WhyAugust 6 at 4:01 AM | americanbankingnews.comLunai Bioworks (Nasdaq: LNAI) Signs Definitive Collaboration Agreement with BrainStorm Therapeutics; Initial Parkinson's Disease Data Readout Targeted for First Half of 2027August 4 at 3:28 PM | prnewswire.comNvidia's CEO says this small device is critical for AI growthA tiny glass device smaller than a fingertip could redefine AI hardware. Nvidia CEO Jensen Huang calls it essential for AI to scale, while Sequoia Capital labels it a holy grail. Stocks tied to this technology have already surged 133 percent, 217 percent, and 320 percent in recent months, according to Brownstone Research analyst Jason Bodner, who identified Nvidia at 4.50.August 6 at 1:00 AM | Brownstone Research (Ad)Lunai Bioworks (Nasdaq: LNAI) Names 10 Defendants in Naked Short Selling Fraud SuitAugust 4 at 9:20 AM | prnewswire.comWhy Did LNAI Stock Soar Over 100% In Pre-Market Trading Today?June 17, 2026 | finance.yahoo.comLunai Bioworks (LNAI) Stock Is Trending Overnight — Here's Why It Spiked Nearly 81% In After-Hours SessionJune 17, 2026 | msn.comLUNAI BIOWORKS: CEO LETTER TO SHAREHOLDERSJune 17, 2026 | prnewswire.comLunai Bioworks (LNAI) Stock Is Trending Overnight — Here's Why It Spiked Nearly 81% In After-Hours SessionJune 17, 2026 | feeds.benzinga.comSee More Headlines LNAI Stock Analysis - Frequently Asked Questions How have LNAI shares performed this year? Lunai Bioworks' stock was trading at $7.0536 at the start of the year. Since then, LNAI shares have decreased by 64.8% and is now trading at $2.48. How were Lunai Bioworks' earnings last quarter? Lunai Bioworks Inc. (NASDAQ:LNAI) announced its earnings results on Friday, May, 15th. The company reported ($0.10) earnings per share (EPS) for the quarter. The company earned $0.02 million during the quarter. When did Lunai Bioworks' stock split? Lunai Bioworks's stock reverse split on Friday, May 22nd 2026.The 1-8 reverse split was announced on Wednesday, May 20th 2026. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 21st 2026. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. How do I buy shares of Lunai Bioworks? Shares of LNAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/15/2026Today8/06/2026Fiscal Year End6/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 LNAI's financial health is in the Green zone, according to TradeSmith. LNAI has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:LNAI CIK1527728 WebN/A Phone(453) 917-9840FaxN/AEmployees20Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$178.01 million Net MarginsN/A Pretax Margin-610,877.00% Return on Equity-1,243.45% Return on Assets-1,617.76% Debt Debt-to-Equity RatioN/A Current Ratio0.19 Quick Ratio0.19 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($9.92) per share Price / Book-0.25Miscellaneous Outstanding Shares4,530,000Free Float4,511,000Market Cap$11.01 million OptionableN/A Beta0.41 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:LNAI) was last updated on 8/6/2026 by MarketBeat.com Staff. From Our PartnersThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThis under $7 stock could be.Just one mile from SpaceX's launchpad sits a small company doing something SpaceX can't - and it still trades ...Freedom Financial | SponsoredHe bet half his $9 billion on ONE stockOne of the most successful fund managers of the past 50 years put more than $4.5 billion - over half his fund ...Stansberry Research | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredBNZI Is Building an AI Growth EngineBanzai International (NASDAQ: BNZI) is drawing fresh attention after a Zacks Rank 2 (Buy) upgrade signaled imp...Huge Alerts | SponsoredThis AI fund sends investors payouts every ThursdayCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lunai Bioworks Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lunai Bioworks With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
